

IGI LABORATORIES, INC  
Form 8-K  
April 30, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT TO**  
**SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): April 25, 2012

**IGI LABORATORIES, INC.**

(Exact name of registrant as specified in charter)

<b>DELAWARE</b>	<b>001-08568</b>	<b>01-0355758</b>
(State or Other Jurisdiction of Incorporation)	(Commission file number)	(I.R.S. Employer Identification Number)

**105 Lincoln Avenue**  
**Buena, New Jersey 08310**  
(Address of principal executive offices)(Zip Code)

**(856) 697-1441**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On April 25, 2012, Jane E. Hager notified IGI Laboratories, Inc. (the Company ) and its Board of Directors of her decision to retire from the Board of Directors and not to stand for re-election at the Company s 2012 annual meeting of stockholders (the Annual Meeting ). Ms. Hager will continue to serve as a director until the Annual Meeting to be held on May 22, 2012.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**IGI LABORATORIES, INC.**

Date: April 30, 2012

By:/s/ Jenniffer Collins  
Name: Jenniffer Collins

Title: Chief Financial Officer